These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 11788129)
21. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering. Jones PH Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089 [TBL] [Abstract][Full Text] [Related]
22. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Athyros VG; Papageorgiou AA; Athyrou VV; Demitriadis DS; Kontopoulos AG Diabetes Care; 2002 Jul; 25(7):1198-202. PubMed ID: 12087019 [TBL] [Abstract][Full Text] [Related]
23. Lipid disorders. Kole LA JAAPA; 2009 Nov; 22(11):54-5. PubMed ID: 19999177 [No Abstract] [Full Text] [Related]
24. Management of lipid disorders in the elderly. Playford DA; Watts GF Drugs Aging; 1997 Jun; 10(6):444-62. PubMed ID: 9205850 [TBL] [Abstract][Full Text] [Related]
25. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones. Florkowski CM Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995 [TBL] [Abstract][Full Text] [Related]
26. Cholesterol-lowering effect of concentrated pomegranate juice consumption in type II diabetic patients with hyperlipidemia. Esmaillzadeh A; Tahbaz F; Gaieni I; Alavi-Majd H; Azadbakht L Int J Vitam Nutr Res; 2006 May; 76(3):147-51. PubMed ID: 17048194 [TBL] [Abstract][Full Text] [Related]
28. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Scott R; Best J; Forder P; Taskinen MR; Simes J; Barter P; Keech A; Cardiovasc Diabetol; 2005 Aug; 4():13. PubMed ID: 16111499 [TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease. Farnier M; Retterstøl K; Steinmetz A; Császár A Diab Vasc Dis Res; 2012 Jul; 9(3):205-15. PubMed ID: 22228773 [TBL] [Abstract][Full Text] [Related]
30. Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes. Brinton EA; Triscari J; Brudi P; Chen E; Johnson-Levonas AO; Sisk CM; Ruck RA; MacLean AA; Maccubbin D; Mitchel YB Lipids Health Dis; 2016 Jul; 15(1):116. PubMed ID: 27405296 [TBL] [Abstract][Full Text] [Related]
31. [Disorders of lipid metabolism in 3 patients with diabetes mellitus type 2]. Wolffenbuttel BH; Huijberts MS Ned Tijdschr Geneeskd; 2001 Apr; 145(16):761-5. PubMed ID: 11346911 [TBL] [Abstract][Full Text] [Related]
32. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058 [TBL] [Abstract][Full Text] [Related]
33. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus. Castaño G; Menéndez R; Más R; Amor A; Fernández JL; González RL; Lezcay M; Alvarez E Int J Clin Pharmacol Res; 2002; 22(3-4):89-99. PubMed ID: 12837046 [TBL] [Abstract][Full Text] [Related]
34. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial. Boden WE Am J Cardiol; 2000 Dec; 86(12A):19L-22L. PubMed ID: 11374850 [TBL] [Abstract][Full Text] [Related]
35. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Fruchart JC; Duriez P Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610 [TBL] [Abstract][Full Text] [Related]
36. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751 [TBL] [Abstract][Full Text] [Related]
37. Achieving optimal lipid goals in patients with coronary artery disease. Karalis DG; Subramanya RD; Hessen SE; Liu L; Victor MF Am J Cardiol; 2011 Mar; 107(6):886-90. PubMed ID: 21247526 [TBL] [Abstract][Full Text] [Related]